Hormone Replacement Therapy: When Symptoms Matter as Much as the Number

Hormone Replacement Therapy: When Symptoms Matter as Much as the Number

Hormone Replacement Therapy Should Treat the Patient, Not Just a Lab Result

Hormone replacement therapy is often approached as though there is a precise laboratory number that separates people who need treatment from people who do not. At Dynamic Psychiatry & Wellness, we believe the reality is more complicated. Hormones influence sleep, mood, energy, cognition, sexual function, body composition, exercise recovery, bone health, motivation, temperature regulation, and many other aspects of physical and emotional functioning. When those systems begin changing, patients can become significantly symptomatic even when a laboratory result technically remains inside a population reference range.

This is why we do not treat laboratory values as dictators. We use them as important pieces of evidence. Symptoms, age, physiology, hormone patterns, free and total hormone levels when appropriate, sleep, sexual function, body composition, medical history, medication effects, alternative explanations, treatment goals, and risk factors all belong in the same clinical picture. A lab result matters, but it does not somehow become more important than the person sitting in front of us telling us that something has clearly changed.

Professional guidelines are useful. They summarize large bodies of research and provide important safety guardrails. But guidelines are written for populations. We treat individual patients. When a patient’s symptoms strongly suggest that changing or inadequate hormone activity is significantly affecting quality of life, we are willing to have a thoughtful conversation about treatment even when that person does not fit neatly into the narrowest traditional treatment box.

When we move beyond the strongest or most conservative consensus indication, we believe the appropriate response is informed consent, not automatic refusal. Patients should understand what is well established, what evidence is emerging, where professional organizations remain more conservative, what risks remain uncertain, and what alternatives are available. Then the patient and clinician can make the decision together.

Hormones Affect Both Mental and Physical Health

A patient experiencing hormone-related changes may not walk into the clinic saying, “My hormones are changing.” They may simply say that they no longer feel like themselves. They may be exhausted despite sleeping, or suddenly stop sleeping well altogether. They may lose sexual desire, struggle to recover after exercise, notice that their weight is shifting even though their habits have not changed, or feel as though their motivation has disappeared. Brain fog may begin interfering with work. A previously resilient person may suddenly feel anxious, irritable, or depressed despite having a good marriage, meaningful work, supportive relationships, and no obvious psychological explanation for the change.

None of those symptoms proves that hormones are the cause. Depression, anxiety, thyroid disease, anemia, sleep apnea, medications, chronic stress, relationship problems, nutritional deficiencies, and many other conditions can produce similar symptoms. That is precisely why thoughtful evaluation matters. It is poor medicine to blame every symptom on hormones. It is equally poor medicine to refuse to consider hormones simply because a laboratory value has not crossed an arbitrary threshold.

Women’s Hormone Therapy Has Changed Dramatically

For years, many women were frightened away from menopausal hormone therapy by broad conclusions drawn from older research that treated different hormone formulations, routes, ages, and clinical situations as though they were interchangeable. We now know that the discussion is far more nuanced. The type of estrogen matters. The route matters. The progesterone or progestin matters. The age at which treatment begins matters. The dose matters. The woman’s medical history matters.

The 2022 Hormone Therapy Position Statement from The Menopause Society recognizes that hormone therapy remains the most effective treatment for menopausal hot flashes and night sweats and is effective in preventing bone loss and fracture. Just as importantly, the statement recognizes that risk varies according to the type of hormone, dose, route, duration, timing, and whether a progestogen is used. In other words, even the major professional organizations are increasingly moving away from treating all hormone replacement therapy as though it were one identical intervention.

That is much closer to the way we approach hormone care. A woman in her forties with disrupted sleep, night sweats, worsening concentration, mood changes, reduced exercise recovery, and changes in sexual function should not necessarily be told to come back when her symptoms become worse or when one laboratory number finally crosses a particular line. Perimenopause is a period of hormonal fluctuation, and an isolated blood draw may not accurately describe what her hormones are doing across the month. We use the clinical story along with the laboratory information.

Estrogen Is More Than a Treatment for Hot Flashes

Estrogen is well known for reducing hot flashes and night sweats, but its influence in the body is much broader. Estrogen affects bone, vaginal and urinary tissues, sexual comfort, sleep, temperature regulation, and multiple systems in the brain. The American College of Obstetricians and Gynecologists recognizes systemic estrogen as the most effective treatment for hot flashes and night sweats and notes its role in protecting against bone loss.

There is also evidence that hormonal changes during the menopause transition can profoundly influence mood. In a randomized clinical trial involving perimenopausal and early postmenopausal women, hormone replacement with estrogen and progesterone combinations reduced the development of depressive symptoms. Randomized Trial of Estradiol, Progesterone, and Depressive Symptoms During the Menopause Transition

That does not mean estrogen should be treated as a universal antidepressant. It means we should stop pretending that mood and hormones live in completely separate worlds. Sometimes a woman needs an antidepressant. Sometimes she needs hormone therapy. Sometimes she needs both. The job of the clinician is to figure out which problem is actually present rather than deciding the answer before the evaluation begins.

Progesterone Is Not Only About Protecting the Uterus

One of the places where our approach may differ from a narrow traditional model involves progesterone. Women with a uterus who receive systemic estrogen generally need adequate progesterone or another progestogen to reduce cancer risk. Older research clearly demonstrated that long-term estrogen only medications increases the risk of endometrial cancer. However, they found that the addition of progesterone lowers that risk substantially. Estrogens, Progesterone, and Endometrial Cancer and Continuous Combined Estrogen Plus Progestin and Endometrial Cancer.

But lowering the risk of uterine cancer is not the only thing progesterone does in the body. Progesterone also acts in the brain to help sleep and calming. A systematic review and meta-analysis of randomized trials examining micronized progesterone and sleep and Randomized Trial of Bedtime Micronized Progesterone in Perimenopause.

That distinction matters clinically. A woman who has had a hysterectomy does not require progesterone to lower cancer risk because she no longer has a uterus. But that does not mean progesterone suddenly stops having effects on her brain, sleep, irritability, relationships or other tissues. For a symptomatic woman—especially one struggling with sleep—we may discuss micronized progesterone even when protecting the uterus is not the reason we are using it. We explain what the evidence supports, what remains uncertain, and why we believe it may be reasonable for her particular symptoms.

Formulation and Route Matter

The phrase “hormone replacement therapy” can be misleading because it makes hormone therapy sound like one identical treatment. It is not. Oral estrogen taken as a pill or capsule is not identical to transdermal estradiol delivered primarily through lotions you apply to the skin. Micronized progesterone is not biologically identical to every synthetic progestin. Different routes affect the body differently because they are absorbed and processed differently and can interact differently with clotting pathways and hormone receptors. Dose matters. Timing matters. How the hormone is taken matters.

Research comparing these approaches has found important differences. A review transdermal estradiol and micronized progesterone described lower blood clot risk with transdermal estradiol than with oral estrogen and noted important differences between micronized progesterone and some synthetic progestins. The 2022 Menopause Society position statement likewise emphasizes that hormone-therapy risk changes depending on formulation, dose, route, timing, duration, and which progestogen is used.

This is why we resist simplistic statements such as “HRT is dangerous” or “HRT is safe.” Those statements are not medically useful. The better question is: Which hormone, delivered how, at what dose, to which patient, at what stage of life, for what purpose, and with what individual risk factors? That is the kind of question that actually helps a patient make a good decision.

What We Mean by Bioidentical Hormones

The term bioidentical is frequently misunderstood. A bioidentical hormone has the same molecular structure as the hormone produced by the human body. Examples include 17β-estradiol and micronized progesterone. This is different from some older hormone regimens that used estrogens from animal sources or synthetic progestins that are not molecularly identical to human progesterone.

At Dynamic Psychiatry & Wellness, we favor bioidentical formulations such as estradiol and micronized progesterone because they are largely identical to the hormones the body naturally makes. Their pharmacology and available safety data are proving safer than some older hormone regimens. That preference does not mean that “bioidentical” is a synonym for “risk-free.” Hormones remain biologically active medications, and dose, route, medical history, cancer risk, cardiovascular risk, clotting risk, and the individual patient still matter.

Testosterone in Men: 300 Is Not a Biological Cliff

The way testosterone is sometimes interpreted is one of the clearest examples of why laboratory numbers should not replace clinical judgment. A commonly used cutoff for low testosterone is approximately 300 ng/dL. But the human body does not recognize 300 as a magical boundary where a man at 299 suddenly develops testosterone-deficiency symptoms while the man at 301 is automatically normal and symptom-free. Some men can have significant symptoms above 300, while other men may feel perfectly well at lower levels. That is why each patient has to be evaluated as an individual and why symptoms need to be part of the decision about whether testosterone replacement therapy is reasonable.

Interestingly, even the American Urological Association Testosterone Deficiency Guideline recognizes this problem. Although the guideline uses 300 ng/dL as a reasonable population-level cutoff, it specifically notes that there are highly symptomatic men with total testosterone levels above 300 who have reported improvement with testosterone treatment and tells clinicians to use clinical judgment in those patients. The same guideline also notes that free testosterone can be helpful when total testosterone is in the borderline range or when a patient is highly symptomatic despite a low-normal total level.

There are other reasons a man may feel symptoms of testosterone deficiency while the total testosterone result appears “normal.” Sex hormone-binding globulin, or SHBG, is one of them. SHBG binds testosterone in the bloodstream, which means a man can have an acceptable-looking total testosterone level while the amount of free or biologically available testosterone is much lower. In ordinary language, the lab may say he has enough testosterone, while his body does not have enough testosterone available to actually use. This is one reason we look at more than one number when the symptoms and the laboratory report do not tell the same story.

At Dynamic Psychiatry & Wellness, symptoms start the conversation. Laboratory findings help us understand the physiology, look for other causes, evaluate safety, and decide whether a treatment trial is reasonable. They are an important part of the evaluation, but they are not the entire evaluation.

Symptoms Still Need an Explanation

Being willing to treat symptomatic patients does not mean assuming every tired man needs testosterone. Fatigue, low libido, decreased motivation, brain fog, depressed mood, loss of strength, and increased body fat can also result from thyroid dysfunction, obesity or metabolic problems, medication effects, chronic stress, depression, relationship problems, poor sleep, substance use, sleep apnea, nutritional problems, or other medical conditions. A broader evaluation remains essential because replacing testosterone will not fix a problem that was never caused by testosterone in the first place.

But once those possibilities have been considered, a highly symptomatic man with borderline or low-normal testosterone should not necessarily be dismissed with, “Your number is technically normal.” There are situations where we may discuss a carefully monitored therapeutic trial after reviewing potential benefits, risks, fertility implications, alternatives, and uncertainty. If the symptoms improve meaningfully and safely, that response becomes additional clinical information. If they do not, responsible medicine means reconsidering the hypothesis instead of simply increasing the dose and insisting that testosterone must have been the answer.

Testosterone Therapy Requires Informed Consent and Monitoring

A more individualized approach does not mean careless prescribing. Exogenous testosterone can suppress the body’s own sperm production, which means fertility needs to be discussed before treatment begins. Men who are actively trying to preserve or achieve fertility may need a different treatment strategy, and in selected situations clinicians may consider alternatives or additional medications rather than simply giving testosterone alone.

Testosterone can also increase red blood cell production, so hematocrit needs to be monitored. Prostate health, cardiovascular history, sleep apnea, medications, symptoms, and other individual risk factors may influence treatment decisions. Our willingness to look beyond a rigid laboratory cutoff comes with an equal commitment to monitoring what happens after treatment begins. The goal is not to create the highest testosterone number possible. The goal is to restore function when inadequate testosterone activity appears to be part of the problem while minimizing unnecessary risk.

Testosterone Therapy in Women

Testosterone matters in women too. It is already recognized by the FDA as massively impactful on their sex drive, particularly after menopause. Global Consensus Position Statement on Testosterone Therapy for Women. But many women also report that estrogen replacement that also has low dose testosterone dramatically improved their energy, focus, mood and more.

The evidence is not limited entirely to older postmenopausal women. The International Society for the Study of Women’s Sexual Health clinical guideline also found various benefits outside sex drive and specifically emphasizes informed consent and shared decision-making because testosterone use for women is often off-label. The same guideline makes an important point that fits our philosophy well: there is no single testosterone level that diagnoses HSDD in women. The clinical picture still matters.

That evidence does not prove that testosterone treats every complaint of fatigue, brain fog, reduced muscle mass, or low motivation in women. When we consider testosterone for broader symptoms, we should be honest that the evidence is less established and still being developed. But less established is not the same thing as forbidden to discuss or having no benefits. Our job is to tell patients what is well proven, what is supported by emerging evidence, what is based more heavily on clinical experience, and what uncertainty remains. Then they can participate meaningfully in the decision.

Hormones and Sexual Wellness

Hormones and sexual health intersect in both women and men, but sexuality can never be reduced to a hormone panel. For women, declining estrogen can contribute to vaginal dryness, tissue changes, discomfort with intercourse, and changes in arousal. Testosterone may influence sexual desire in appropriately selected women. Progesterone-related improvement in sleep may even indirectly improve sexual functioning because someone who is chronically exhausted often has far less capacity for desire and connection.

For men, testosterone deficiency may affect libido, spontaneous erections, energy, body composition, and sexual function. But hormones are still only one part of the picture. Antidepressant side effects, anxiety, depression, trauma, relationship conflict, sexual pain, stress, sleep deprivation, shame, and learned beliefs about sexuality can all affect desire. We therefore evaluate hormone-related sexual symptoms as part of the entire sexual wellness picture rather than assuming every sexual problem can be solved by changing one laboratory number.

Hormones, Mood, and Brain Function

One reason hormone concerns are particularly relevant at Dynamic Psychiatry & Wellness is that we treat mental and physical health together. Hormonal changes can contribute to symptoms that look psychiatric: depressed mood, emotional volatility, fatigue, poor concentration, sleep disruption, anxiety, loss of motivation, and brain fog. The brain is part of the body, and there is no good medical reason to pretend that hormones can affect almost every organ system except the one responsible for mood and thinking.

The study of estradiol and micronized progesterone during the menopause transition is a good example. Women receiving active hormone therapy developed depressive symptoms substantially less often than women receiving placebo. Randomized Hormone Therapy and Depression Trial That finding does not mean every depression is hormonal, and it does not mean hormone therapy replaces traditional psychiatric treatment. It means hormonal physiology deserves to be considered when the clinical story points in that direction.

Sometimes an antidepressant is the right treatment. Sometimes hormone therapy is addressing an important physiological driver. Sometimes both are appropriate. Sometimes neither is the primary answer. Our job is to determine which situation is actually present.

Laboratory Values Are Data, Not Dictators

Laboratory testing matters. We use it to understand physiology, identify unexpectedly high or low values, evaluate free versus bound hormones when relevant, establish baselines, monitor treatment, and look for alternative explanations. But reference ranges are statistical tools created from populations. They do not create a biological switch at one exact number where symptoms suddenly begin or disappear.

This is especially important in perimenopause because estrogen and progesterone can fluctuate substantially, sometimes over relatively short periods of time. One blood draw may catch the numbers at their highest point and not represent what a woman is experiencing across several weeks or months. It also matters in testosterone evaluation because total testosterone can be influenced by SHBG, metabolic health, medications, illness, age, and other physiological variables.

We therefore combine objective measurement with symptoms and function. If the laboratory result and the patient tell two very different stories, our response is not to ignore one of them. Our response is to investigate further.

Informed Consent Allows More Individualized Medicine

There is a difference between irresponsible prescribing and practicing outside the narrowest interpretation of a professional guideline. At Dynamic Psychiatry & Wellness, informed consent becomes especially important when treatment enters an area where evidence is promising but consensus recommendations remain more conservative. We want patients to understand what we know with reasonable confidence, what the research supports, what the research does not yet prove, whether a particular use is off-label, what risks are known, what risks remain uncertain, what alternatives exist, what monitoring will be used, and what would cause us to stop or change treatment.

That approach respects both science and patient autonomy. Medical knowledge changes. Professional recommendations change. Treatments that were once discouraged can become accepted years later as better research accumulates. We do not believe patients should be misled into thinking uncertainty does not exist, but we also do not believe they should necessarily be required to continue suffering until every professional organization reaches exactly the same conclusion.

Hormone Therapy Is Not One Risk Category

One of the most damaging simplifications in discussions of hormone replacement therapy is speaking about “the risk of HRT” as though every hormone, dose, route, regimen, and patient carries exactly the same risk. They do not. The 2022 Menopause Society Hormone Therapy Position Statement specifically recognizes that risk varies based on hormone type, dose, duration, route, timing of treatment, and whether a progestogen is used.

Older endometrial-cancer research also demonstrates why the details matter. Long-term unopposed estrogen was associated with substantially increased endometrial-cancer risk, while the addition of adequate progestogen changed that risk. Later randomized data examining continuous combined estrogen plus progestin again showed that hormone regimen matters. Women’s Health Initiative: Continuous Combined Estrogen Plus Progestin and Endometrial Cancer

Research examining transdermal estradiol and micronized progesterone has also suggested a more favorable clotting-risk profile than some older oral estrogen and synthetic-progestin regimens. That does not mean modern bioidentical hormone therapy has zero risk. It means modern hormone treatment should not automatically inherit every risk estimate from every older hormone formulation and every older treatment strategy.

What to Expect From Hormone Evaluation at Dynamic Psychiatry & Wellness

Hormone evaluation is part of the larger comprehensive wellness evaluation and starts with the patient’s story. We want to know what changed, when it changed, and how it is affecting daily life. We look at mood, sleep, energy, cognition, sexual function, menstrual or menopausal changes, exercise performance, muscle and body-composition changes, weight, medical history, medications, relationships, stress, and treatment goals. Laboratory testing is then selected based on the clinical question rather than ordered simply to create an impressive-looking panel of numbers.

When treatment appears reasonable, we discuss the potential benefits, risks, established evidence, areas of uncertainty, and alternatives. The patient participates in deciding how aggressive or conservative they want to be within medically reasonable limits. Once treatment begins, symptoms remain important. We want to know whether sleep improved, whether hot flashes changed, whether libido returned, whether energy and mental clarity are better, whether exercise recovery improved, whether mood changed, and whether unwanted effects appeared. Laboratory monitoring remains important too, especially when treatment could move hormone levels or blood counts into an unsafe range. The goal is not simply to normalize a laboratory value. The goal is to improve the person.

Hormone Replacement Therapy Should Improve Function

At Dynamic Psychiatry & Wellness, we are comfortable being more proactive about hormone treatment than some traditional practices because we repeatedly see what happens when patients are told that suffering is simply part of aging. A woman should not necessarily have to edure depression and anxiety or wait until menopause is complete before someone takes severe night sweats, poor sleep, sexual changes, brain fog, and mood changes seriously. A woman without a uterus should not automatically be told that progesterone could have no possible therapeutic role simply because she no longer needs endometrial protection. A highly symptomatic man should not automatically be dismissed because his total testosterone happened to measure 305 instead of 295.

Those numbers matter, but they are not the entire patient. Total treatment combines hormone considerations as part of the metal health optimization plan. This should include considerations for published research, clinical judgment, symptoms, physiology, laboratory evidence, individual risk, patient preference, and careful monitoring. Sometimes that leads to exactly the same recommendation a conservative guideline would make. Sometimes, after an informed discussion, it leads to a more individualized treatment choice. The patient deserves to understand that difference rather than simply being told, “Your labs are normal, so there is nothing we can do to help your mental wellbeing or homones.”

The Goal Is Full Mental and Physical Health

Hormone replacement therapy is not about making everyone younger, prescribing hormones to everyone who feels tired, or chasing artificially high laboratory levels. It is about recognizing that hormones are biologically powerful and that inadequate or changing hormone activity can substantially affect how some people feel and function.

When hormone changes are part of the problem, responsible replacement can improve symptoms that patients may previously have been told they simply needed to tolerate. When hormones are not the problem, responsible care means continuing to look for the real cause rather than forcing the hormone explanation to fit.

That is the model we use at Dynamic Psychiatry & Wellness. We treat the symptoms. We measure the physiology. We examine the risks. We review the evidence. We explain uncertainty. We listen to the patient. Then we make the decision together.

Because the goal of hormone replacement therapy should never be to treat a number. The goal is to help the person function and feel better while using hormone therapy thoughtfully, safely, and with informed consent.